Top Mid-Cap Biotech Companies Increased Revenues to $26.5 Billion in 2014, says GlobalData

  • Combined total revenues for peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014
  • Rise was driven by Regeneron and Alexion, both of which posted sales of more than $2 billion in 2014, says analyst
LONDON, UK (GlobalData), 7 April 2015 - The combined total revenues for the peer group of 35 mid-cap biotech companies increased from $24.8 billion in 2013 to $26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9%, according to research and consulting firm GlobalData.
 
The company's latest report* states that this growth was marginally slower than during the previous five years, as total revenues for this peer group expanded at a CAGR of 25.2% between 2009 and 2013.
 
Adam Dion, MS, GlobalData's Healthcare Industry Analyst, says the rise in biotech peer group total revenue over the past year was driven by Regeneron and Alexion, both of which posted sales of more than $2 billion in 2014.
 
Dion explains: "Regeneron's sales grew by 34% in 2014, as the company continued its commercialization of Eylea (afilibercept) to markets outside the US, including for the treatment of macular edema secondary to central retinal vein occlusion in both the EU and Japan.
 
"Alexion saw sales from its orphan drug Soliris (eculizumab) increase from $1.6 billion in 2013 to $2.2 billion in 2014. Alexion reported a higher volume of unit shipments and better-than-expected demand for Soliris across all geographic regions, especially in the EU, thanks to a reimbursement agreement with the French government."
 
The analyst adds that Pharmacyclics, which was acquired by pharmaceutical giant AbbVie last month, was the peer group revenue growth leader in 2014. Its sales shot up by 180% in 2014 to $729 million, representing an absolute dollar increase of nearly $470 million.
 
GlobalData attributes this surge to Pharmacyclics recognizing nearly $493 million in new product revenue from sales of Imbruvica (ibrutinib), the company's first-in-class BTK inhibitor approved to treat blood cancer patients with chronic lymphocytic leukemia and mantle cell lymphoma.
 
By contrast, some companies experienced sales decreases, most notably Vertex, which saw revenues decline by 52.1%, from $1.2 billion in 2013 to $580.4 million in 2014.
 
Dion comments: "This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3 million compared with 2013, primarily as a result of increased competition from Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir)."
 
*PharmaLeaders: Mid-Cap Biotechnology Benchmark Report – Sales Forecasts and Product Valuations of Innovative Biotechs
 
-ENDS-
 
-NOTES TO EDITORS-
 
This report provides analysis of the key drivers and trends shaping the biotechnology sector, including drivers of financial growth and research and development spending, US Food and Drug Administration approvals, generic erosion, corporate strategies, orphan drugs and asset value creation. It includes net present values and six-year forecasts for key drugs approved in 2014.
 
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData's team of industry experts.
 
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
 
-ABOUT GLOBALDATA-
 
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
 
For more information, please contact our Press Office on +44 (0)1204 543 537 or at [email protected]
 
Gain access to our latest press releases and expert analysis on developments in your industry. Subscribe to our RSS feed for the Healthcare sector, or connect with us on:
 
Facebook | LinkedIn | Twitter 

 

 

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.